article thumbnail

Patents: a necessary evil?

European Pharmaceutical Review

10 There is a fear that such practices discourage innovative approaches, impacting on patient welfare. Patent Protection of Pharmacologically Active Metabolites: Theoretical and Technological Analysis on the Jurisprudence of Four Regions. 23 April 2013. Cited 25 September 2022]. Li-dar Wang R, Huang P-C. 29(3), article 2.

article thumbnail

Regenerative potential: cell?based therapies for heart failure

European Pharmaceutical Review

Pharmacological therapies mainly address symptoms and unfortunately a significant number of patients do not respond adequately, progressing to congestive heart failure and eventually needing a heart transplant. As this is an autologous therapy, there is a lot of patient-to-patient variability. 1 Furthermore, there are 63.3

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Digital Self-Neuromodulation Therapy for PTSD: Interview with Oded Kraft, CEO of GrayMatters Health

Medgadget

The system uses the patient’s EEG data to calculate a value for the amygdala-derived-EFP biomarker, and meanwhile the patient tries various mental strategies that may help to reduce the value. These treatments at times come with a long list of side effects, leaving many patients in search of an effective long-term solution.

article thumbnail

Female sexual interest drug reaches tipping point with Phase III plans

Pharmaceutical Technology

The company is aiming to enrol the first patient in the ALETTA Phase III trial in Q1 or Q2 of 2023, says Dr. Jan van der Mooren, Freya’s chief medical officer (CMO). Moreover, any potential use of Lybrido or Lybridos would also come with a screening test that will determine which of these drugs will benefit the patient, says Simon.